07:00 , Aug 15, 2011 |  BC Week In Review  |  Company News

Epigenomics genomics, diagnostic news

Epigenomics will restructure and reduce headcount by about 39 (46%) to 45 and will discontinue early stage research to focus on the U.S. market. Details on the cuts were not disclosed. Epigenomics said it is...
07:00 , May 27, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Fibrillation; tachycardia Paired-like homeodomain transcription factor 2 (PITX2); short stature homeobox 2 (SHOX2) Studies in mice and in vitro suggest that PITX2 agonists or...
07:00 , Jun 22, 2009 |  BC Week In Review  |  Clinical News

PC-MCT: Pivotal trial additional data

Additional data from an analysis of tissue samples taken from 476 patients with prostate cancer showed that biochemical recurrence-free survival at 5 years post-prostatectomy was 85% and 61% for patients with low and high respective...
07:00 , Oct 20, 2008 |  BC Week In Review  |  Clinical News

PC-MCT: Pivotal trial data

Analysis of tissue samples taken from 476 patients with prostate cancer showed that those with elevated paired-like homeodomain transcription factor 2 (PITX2) gene methylation levels had a 3-fold higher risk of relapse following prostatectomy compared...
07:00 , Apr 10, 2006 |  BC Week In Review  |  Clinical News

Epigenomics preclinical data

Data from tumor tissues taken from prostate cancer patients showed that those who tested positive for methylation of paired-like homeodomain transcription factor 2 gene ( PITX2 ) were 3 times more likely to experience cancer...